n-3 and n-6 Fatty acids are independently associated with lipoprotein-associated phospholipase A2 in the Multi-Ethnic Study of Atherosclerosis

British Journal of Nutrition

Volumn 110, Issue 9, 2013, Pages 1664-1671

  Steffen, Brian T ^a   Steffen, Lyn M ^b   Liang, Shuang ^a   Tracy, Russell ^c   Jenny, Nancy Swords ^c   Tsai, Michael Y ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Fatty acids; Lipoprotein associated phospholipase; Lipoprotein associated phospholipase A2; n 3

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; DOCOSAHEXAENOIC ACID; GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; LINOLEIC ACID;

AGED; ATHEROSCLEROSIS; BLOOD; FEMALE; HUMAN; INFLAMMATION; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; ATHEROSCLEROSIS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FEMALE; GAMMA-LINOLENIC ACID; HUMANS; INFLAMMATION; LINOLEIC ACID; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS;

EID: 84891948739     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114513000949     Document Type: Article

References (34)

1. MacPhee CH, Moores KE, Boyd HF, et al. (1999) Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 338, 479–487.
2. Sudhir K (2006) Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction. Vasc Health Risk Manag. 2, 153–156.
3. Gazi I, Lourida ES, Filippatos T, et al. (2005) Lipoprotein-associated phospholipase A2 activity is a marker of small dense LDL particles in human plasma. Clin Chem. 51, 2264–2273.
4. Serruys PW, García-García HM, Buszman P, et al. (2008) Integrated biomarker and imaging study-2 investigators. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 118, 1172–1182.
5. Jenny NS, Solomon C, Cushman M, et al. (2010) Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study. Atherosclerosis. 209, 528–532.
6. Kris-Etherton PM, Harris WS, Appel LJ, et al. (2002) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 106, 2747–2757.
7. Dyerberg J, Bang HO, Stoffersen E, et al. (1978) Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet. 2, 117–119.
8. Pedersen MW, Koenig W, Christensen JH, et al. (2009) The effect of marine omega-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. Eur J Nutr. 48, 1–5.
9. Nelson TL, Hokanson JE & Hickey MS (2011) Omega-3 fatty acids and lipoprotein associated phospholipase A(2) in healthy older adult males and females. Eur J Nutr. 50, 185–193.
10. Schaefer EJ, Asztalos IB, Gleason JA, et al. (2010) Abstract 20007: effects of eicosapentaenoic acid, docosahexaenoic acid, and olive oil on cardiovascular disease risk factors. Circulation 122, A20007 (Core 2. Epidemiology and prevention of CV disease: physiology, pharmacology and lifestyle. Session title: nutritional epidemiology and healthy eating).
11. Davidson MH, Maki KC, Bays H, et al. (2009) Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol. 3, 332–340.
12. Maki KC, Bays HE, Dicklin MR, et al. (2011) Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. J Clin Lipidol. 5, 483–492.
13. Saadatian-Elahi M, Slimani N, Chajès V, et al. (2009) Plasma phospholipid fatty acid profiles and their association with food intakes: results from a cross-sectional study within the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr. 89, 331–346.
14. Patel PS, Sharp SJ, Jansen E, et al. (2010) Fatty acids measured in plasma and erythrocyte-membrane phospholipids and derived by food-frequency questionnaire and the risk of new-onset type 2 diabetes: a pilot study in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk cohort. Am J Clin Nutr. 92, 1214–1222.
15. Bild DE, Bluemke DA, Burke GL, et al. (2002) Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol. 156, 871–881.
16. Cao J, Schwichtenberg KA, Hanson NQ, et al. (2006) Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids. Clin Chem. 52, 2265–2272.
17. Cushman M, Cornell ES, Howard PR, et al. (1995) Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 41, 264–270.
18. Brilakis ES, Khera A, McGuire DK, et al. (2008) Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. Atherosclerosis. 199, 110–115.
19. Hatoum IJ, Nelson JJ, Cook NR, et al. (2010) Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. Am J Clin Nutr. 91, 786–793.
20. Hirschler V, Meroño T, Maccallini G, et al. (2011) Association of lipoprotein-associated phospholipase A(2) activity with components of the metabolic syndrome in apparently healthy boys. Cardiovasc Hematol Agents Med Chem. 9, 78–83.
21. Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, et al. (2010) Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375, 1536–1544.
22. Schmidt EB, Koenig W, Khuseyinova N, et al. (2008) Lipoprotein-associated phospholipase A2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine omega-3 fatty acids. Atherosclerosis. 196, 420–424.
23. Spite M & Serhan CN (2010) Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res. 107, 1170–1184.
24. Wu X, Zimmerman GA, Prescott SM, et al. (2004) The p38 MAPK pathway mediates transcriptional activation of the plasma platelet-activating factor acetylhydrolase gene in macrophages stimulated with lipopolysaccharide. J Biol Chem. 279, 36158–36165.
25. Wang WY, Li J, Yang D, et al. (2010) OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways. Cardiovasc Res. 85, 845–852.
26. Arita M, Ohira T, Sun YP, et al. (2007) Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol. 178, 3912–3917.
27. Chen H, Li D, Chen J, et al. (2003) EPA and DHA attenuate ox-LDL-induced expression of adhesion molecules in human coronary artery endothelial cells via protein kinase B pathway. J Mol Cell Cardiol. 35, 769–775.
28. Madonna R, Salerni S, Schiavone D, et al. (2011) Omega-3 fatty acids attenuate constitutive and insulin-induced CD36 expression through a suppression of PPAR α/γ activity in microvascular endothelial cells. Thromb Haemost. 106, 500–510.
29. Hennig B, Lei W, Arzuaga X, et al. (2006) Linoleic acid induces proinflammatory events in vascular endothelial cells via activation of PI3K/Akt and ERK1/2 signaling. J Nutr Biochem. 17, 766–772.
30. Steffen BT, Steffen LM, Tracy R, et al. (2012) Obesity modifies the association between plasma phospholipid polyunsaturated fatty acids and markers of inflammation: the Multi-Ethnic Study of Atherosclerosis. Int J Obes (Lond). 36, 797–804.
31. Serhan CN (2002) Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat. 68–69, 433–455.
32. Wu SH, Liao PY, Dong L, et al. (2008) Signal pathway involved in inhibition by lipoxin A(4) of production of interleukins induced in endothelial cells by lipopolysaccharide. Inflamm Res. 57, 430–437.
33. Schaefer EJ, McNamara JR, Asztalos BF, et al. (2005) Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol. 95, 1025–1032.
34. Mohler ER 3rd, Ballantyne CM, Davidson MH, et al. (2008) The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 51, 1632–1641.